Program
antihemophilic factor, human recombinant
Also written as “Antihemophilic factor, recombinant, manufactured protein-free”, “Recombinant Factor VIII (BAY81-8973)” and “ADVATE”.
Its studies are mostly in Hemophilia A · von Willebrand Diseases, led by 3 companies.
Drug pageAntihemophilic factor, human recombinant: every studyAll 23 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takedaits history only | 101 open or running | phase 4since Oct 21, 2005 | Sep 8, 2005 | Nov 25, 2027phase 3 · NCT07129343 |
| Bayer | 50 open or running | phase 4since Sep 4, 2020 | Dec 8, 2009 | none ahead |
| Novo Nordiskits history only | 10 open or running | phase 1since Feb 4, 2009 | Feb 4, 2009 | none ahead |
Also a collaborator on its studies: Takeda Development Center Americas and Baxter Innovations.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Bayer only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 8, 2009First study: phase 3 study in Blood Coagulation DisordersFirst studyNCT01029340 · 74 enrolled · United States, Argentina, Austria and more
- Nov 2, 2010Phase 3 study in Hemophilia ANCT01233258 · 80 enrolled · United States, Argentina, China and more
- Feb 18, 2011Phase 3 study in Hemophilia ANCT01311648 · 94 enrolled · United States, Argentina, Bulgaria and more
- Jun 24, 2015Phase 1 study in Hemophilia ANCT02483208 · 18 enrolled · Bulgaria
- Sep 4, 2020Phase 4 study in Hemophilia ANCT04565236 · 45 enrolled · China
- Oct 21, 2026Primary completion moved from 2027-09-30 to 2028-03-31Date moved laterno phase · +6 months · NCT07446010
TargetBeta
“Coagulation factor VIII exogenous protein”ChEMBL 37, by rule
Other programs on F8
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| efanesoctocog alfarule | Sanofi | phase 4 | 12 |
| omfiloctocog alfarule | Sinocelltech Group | phase 4 | 6 |
| lonoctocog alfarule | CSL | phase 3 | 4 |
Studies
All 5 Bayer leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04565236Hemophilia A · China | 4 | Completed | Mar 15, 2024 | 45 |
| NCT02483208Hemophilia A · Bulgaria | 1 | Completed | Jul 2015 | 18 |
| NCT01311648Hemophilia A · United States, Argentina, Bulgaria and more | 3 | Completed | Sep 9, 2019 | 94 |
| NCT01233258Hemophilia A · United States, Argentina, China and more | 3 | Completed | Dec 2012 | 80 |
| NCT01029340Blood Coagulation Disorders · United States, Argentina, Austria and more | 3 | Completed | Jun 2012 | 74 |
How it is read
Names in the registry
- “Antihemophilic factor, recombinant, manufactured protein-free”, 8 entries
- “Recombinant Factor VIII (BAY81-8973)”, 3 entries
- “ADVATE”, 2 entries
- “Recombinant Factor VIII (Kovaltry, BAY81-8973)”, 2 entries
- “Antihemophilic Factor (Recombinant)”, 1 entry
Codes read as this program: BAY818973.
Conditions, from the studies’ own filings
- Hemophilia A, 14 studies
- von Willebrand Diseases, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.